GlaxoSmithKline filed an application Monday with the Food and Drug Administration seeking approval for a triple combination therapy for patients with chronic obstructive pulmonary disease (COPD).
The product was developed by GlaxoSmithKline (NYSE: GSK) in a partnership with South San Francisco-based Innoviva (NASDAQ: INVA),which previously operated as Theravance.
Dave Allen, head of respiratory research and development at GlaxoSmithkline, or said treatment is geared to COPD patients who are often must…
Source: bizjournals.com